Epitomee Medical

Executive Summary

Epitomee Medical is an Israeli public med-tech company pioneering a novel polymer-based, self-expanding hydrogel capsule designed to deliver targeted therapies along the gastrointestinal (GI) tract. The platform leverages mechano-sensory stimulation and localized drug release to manage chronic conditions such as obesity and metabolic disorders. Currently at the preclinical stage, Epitomee's technology offers a unique non-systemic approach that could address the significant unmet need in obesity treatment, particularly for patients seeking alternatives to injectable GLP-1 agonists. The company's capsule is designed to be swallowed and expands in the stomach, providing a combination of mechanical satiety and localized drug delivery, potentially reducing side effects and improving compliance. Epitomee's public listing provides transparency and access to capital markets, though its small size (10-50 employees) and early development phase imply high risk and long timelines to commercialization.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept studies in obesity models60% success
• TBDPartnership or licensing agreement with a larger pharmaceutical company30% success
• Q1 2027Submission of IND or equivalent regulatory filing for first-in-human trials20% success